For national guidance on this topic please see:
ACBS Indication:
Cystic fibrosis
Not suitable for use in child under 4 years
| Pack |
|---|
| 60 tablet |
Not recommended for child over 3 years
| Pack |
|---|
| 60 ml |
Not suitable for use in child under 10 years
Contains bovine derivatives, soya
| Pack |
|---|
| 60 capsule |
| Pack |
|---|
| 28 tablet |
| Pack |
|---|
| 56 tablet |
| 28 tablet |
| Pack |
|---|
| 56 sachet |
| Pack |
|---|
| 56 sachet |
| Pack |
|---|
| 56 sachet |
Funded by NHS England/CCG if prescribed by GP's.
Funding now rests with NHS England for this treatment. GP's should NOT accept prescribing responsibility for NEW patients.
For existing patients, GP's should continue to prescribe these treatments. NHS England are looking to repatriate these patients in the future. The medicines Management Team will be in contact with prescribers when they have more information.
Indication - recommended option for Cystic Fibrosis if rhDNase or other osmotic drugs are inappropriate and lung function is rapidly declining
| Pack |
|---|
| 15 capsule |
| Pack |
|---|
| 10 capsule |
| Pack |
|---|
| 280 capsule |
Paediatric CF team recommendation only.
Patient should be reviewed once they have reached adult age.
| Pack |
|---|
| 60 capsule |
| Pack |
|---|
| 7 ml |
For children with cystic fibrosis (CF) who are taking a cystic fibrosis transmembrane conductance regulator modulator.
| Pack |
|---|
| 60 capsule |
| Pack |
|---|
| 7 ml |
For treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over (NICE TA1085)
| Pack |
|---|
| 56 tablet (4 x 14 tablets) |
| Pack |
|---|
| 84 tablet (4 x 21 tablets) |







